ClinicalTrials.gg
CompletedNCT06389916Updated Nov 9, 2026

Euclid Phoenix Lens Design Trial

An interventional study of Euclid orthokeratology MAX (current design) and Euclid orthokeratology MAX Phoenix (new design) in Myopia and Cornea, sponsored by Euclid Systems Corporation. Completed at 5 sites in United States. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Euclid Systems Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.
Updated Nov 9, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Enrollment
227th of 294
39 · median 68
Started
2023
with 30 others
No phase
243 of 342
16 open now
Registered
292nd of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 227th largest by enrollment of the 294 interventional ones that give a count, is one of 31 that started in 2023, is one of 243 with no phase, and was the 292nd registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

The "first fit" success rate of the current Euclid orthokeratology "MAX" lens design will be compared to that of the new Euclid orthokeratology MAX "Phoenix" lens design in 30 children.

Read the detailed description

The primary objective of this trial is to provide an assessment of the "first fit" success of the Euclid orthokeratology "Phoenix" lens design versus its current "MAX" lens design when used by practitioners with moderate experience with fitting Euclid MAX orthokeratology lenses.

The hypothesis to be tested is that the "first fit" success of the redesign Euclid MAX "Phoenix" lens design is greater than that of the current MAX lens design.

The primary outcome variable is the percentage of participants successfully fit with the first lenses empirically ordered for the existing MAX lens design versus a modified MAX lens ("Phoenix") design.

This clinical investigation will be a prospective, randomized, double-masked two-arm non-crossover trial.

03

Conditions studied

  • Myopia
  • Cornea
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be of legal age or, if under legal age have written consent of their parent or guardian to participate.
  • Sign written (and the California Bill of Rights, if applicable).
  • Ages 6-18 (inclusive) and able to understand and assent to participation
  • Have need of optical correction for myopia, from -1.00 to -5.00 diopters (D).
  • Have a refractive astigmatism of less than -1.50 D.
  • Have a minimum Best Spectacle Corrected Visual Acuity (BSCVA) of 20/40 or better.
  • Have reasonable expectations of improvement in visual acuity with the Euclid Orthokeratology Lens of 20/40 or better after overnight wear without corrective aids.
  • Be at least 18 years old to give informed consent.
  • Not a current or former wearer of orthokeratology lenses
  • Not a current wearer of soft contact lenses
  • Have acceptable or optimal fit with study lenses and be willing to wear these lenses as directed for the duration of the study.
  • On examination, have ocular findings considered to be within normal limits
  • Normal binocularity (no amblyopia or strabismus, and no anisometropia of greater than 2.00D)
  • Be willing and able to follow instructions and attend the schedule of follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Does not meet the any of the above inclusion criteria
  • Not able or willing to provide and assent
  • Requires concurrent ocular medication
  • Eye injury or surgery within twelve weeks immediately prior to enrollment
  • Pre-existing ocular condition that would preclude contact lens fitting
  • Currently enrolled in an ophthalmic clinical trial
  • Pregnant or lactating or expect to become pregnant during the trial
  • Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions.
  • Allergy or sensitivity to any product used in this trial
  • Any systemic disease including disease, immunocompromising diseases, connective tissue disease, atopic diseases, insulin dependent diabetes, use of medications including and antimetabolites that may affect the eye or be exaggerated by contact lenses.
  • Strabismus/amblyopia
  • Habitually uncorrected anisometropia ≥2.00
  • Subjects who have undergone corneal refractive surgery
  • Subjects with severe corneal irregularity contraindicating lens wear
  • Inability to wear contact lenses, or an unacceptable contact lens fit
  • Poor or unacceptable fit with any study lens
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Euclid orthokeratology MAX (current design)

    Euclid Orthokeratology (oprifocon A) Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.

    Device: Euclid orthokeratology MAX (current design)

  • Experimental
    Euclid orthokeratology MAX Phoenix (new design)

    Euclid Orthokeratology (oprifocon A) Contact Lenses are lathe cut contact lenses with spherical posterior surfaces. The posterior curve is selected to properly fit an individual eye for orthokeratology and the anterior curve is selected to provide the necessary optical power for a temporary reduction of myopia. A peripheral curve system on the posterior surface allows tear exchange between the lens and the cornea.

    Device: Euclid orthokeratology MAX Phoenix (new design)

Interventions

  • DeviceEuclid orthokeratology MAX (current design)

    The current lens design

  • DeviceEuclid orthokeratology MAX Phoenix (new design)

    The new lens design

06

What researchers measure

Primary outcomes

  1. First fit success rate

    Percentage of children successfully fit in the first lens pair ordered (as determined by the PI)

    Time frame: 1 month

07

Study locations

5 sites
  • Insight Vision Center Optometry
    Costa Mesa, California 92626, United States
  • Dau Family Eye Care
    Saint Johns, Florida 32259, United States
  • Cornea and Contact Lens Institute of Minnesota
    Edina, Minnesota 55436, United States
  • Somerset Eye Care
    North Brunswick, New Jersey 08902, United States
  • Treehouse Eyes
    Tysons Corner, Virginia 22182, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2024, 6 months.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 6 months is close to that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2024 → May 2024 and completion Apr 2024 → May 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Apr 29, 2024
StartActual
Nov 1, 2023
Primary completionActual
May 9, 2024was Apr 2024
CompletionActual
May 9, 2024was Apr 2024
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Apr 2024→May 9, 2024 (actual)
Nov 9, 2026
Study completion
Apr 2024→May 9, 2024 (actual)
Nov 9, 2026
Enrollment
30 (estimated)→39 (actual)
Nov 9, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHave need of optical correction for myopia, from -1.00 to -5.00 dioptcrsdiopters (D).
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Primary completion Apr 2024→May 9, 2024 (now actual)
    Study completion Apr 2024→May 9, 2024 (now actual)
    Enrollment 30 (estimated)→39 (actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHave need of optical correction for myopia, from -1.00 to -5.00 dioptcrsdiopters (D).
    + 3 other changes: verification date, responsible party and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06389916
Lead sponsor
Euclid Systems Corporation
Collaborators
ClinTrialSolutions, LLC
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Nov 1, 2023
Primary completion
May 9, 2024
Completion
May 9, 2024
Last update
Nov 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion